TrivarX Limited (AU:TRI)
ASX:TRI
Want to see AU:TRI full AI Analyst Report?
TRI Stock Chart & Stats
AU$0.02
<AU$0.01(6.67%)
At close: 4:00 PM EST
AU$0.02
<AU$0.01(6.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume87.40K
Average Volume (3M)1.22M
Market Cap
AU$21.92M
Enterprise ValueAU$17.38M
Total Cash (Recent Filing)AU$1.25M
Total Debt (Recent Filing)AU$169.03K
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageA debt-to-equity ratio of ~0.013 indicates minimal financial leverage, materially lowering solvency and refinancing risk. For a small, loss-making healthcare information services firm this conservatism provides durable runway flexibility, making capital shocks easier to absorb over months.
Solid Equity And Asset BaseAn equity base of ~12.65M and assets of ~13.48M supply a meaningful capital cushion for operating losses and product development. This capital base supports multi-month operations and strategic initiatives without immediate dilution, strengthening structural resilience.
Improving Cash Burn TrajectoryFree cash flow improving from -3.70M to -0.19M shows a durable reduction in cash burn and progress toward self funding. While still negative, the multiyear improvement signals operational control and a smaller incremental financing need over the coming 2-6 months.
Bears Say
Ongoing UnprofitabilityConsecutive net losses (-1.24M then -0.94M) indicate the business has not reached profitability. Persistent deficits erode equity over time unless offset by sustained cash flow improvements or external capital, posing a structural risk to long-term viability absent clear revenue generation.
Negative Operating And Free Cash FlowNegative OCF and FCF in FY2025 show the company is not yet self-funding and remains reliant on financing or equity to cover operations. Continued outflows compress strategic optionality and may force dilution or limit investment in product development over the medium term.
No Reported RevenueZero reported revenue across reporting periods removes visibility into product-market fit and scalable demand. Without demonstrable revenue, margin dynamics are untestable and the firm faces structural uncertainty about commercial viability and the pace at which costs can be covered.
TrivarX Limited News
TRI FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is AU$21.92M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 129 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in AU:TRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---